Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis

Pharmaceutical Research

Volumn 25, Issue 10, 2008, Pages 2427-2439

  Prakash, Jai ^a   De Borst, Martin H ^b   Van Loenen Weemaes, Annemiek M ^a   Lacombe, Marie ^c   Opdam, Frank ^c   Van Goor, Harry ^b   Meijer, Dirk K F ^a   Moolenaar, Frits ^a   Poelstra, Klaas ^a   Kok, Robbert J ^a,d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Kreatech Biotechnology BV   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Lysozyme; Proximal tubular cells; Transforming growth factor; Tyrosine kinase inhibitor; Unilateral ureteral obstruction

Indexed keywords

3 (PYRIDIN 2 YL) 4 (4 QUINONYL) 1H PYRAZOLE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DRUG CARRIER; LYSOZYME; PHOSPHOTRANSFERASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG URINE LEVEL; GENE EXPRESSION; HUMAN; HUMAN CELL; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SINGLE DRUG DOSE; URETER OBSTRUCTION; WISTAR RAT;

ANIMALS; CELL LINE; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; DRUG CARRIERS; EPITHELIAL CELLS; FIBROBLASTS; FIBROSIS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; MALE; MURAMIDASE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; URETERAL OBSTRUCTION;

EID: 51649106180     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9515-x     Document Type: Article

References (26)

1. E. P. Bottinger M. Bitzer 2002 TGF-beta signaling in renal disease J. Am. Soc. Nephrol 13 2600 2610
2. M. Zeisberg R. Kalluri 2004 The role of epithelial-to-mesenchymal transition in renal fibrosis J. Mol. Med 82 175 181
3. A. A. Eddy 1996 Molecular insights into renal interstitial fibrosis J. Am. Soc. Nephrol 7 2495 2508
4. H. W. Schnaper T. Hayashida A. C. Poncelet 2002 It's a Smad world: regulation of TGF-beta signaling in the kidney J. Am. Soc. Nephrol 13 1126 1128
5. N. J. Laping 2003 ALK5 inhibition in renal disease Curr. Opin. Pharmacol 3 204 208
6. J. S. Sawyer D. W. Beight K. S. Britt B. D. Anderson R. M. Campbell T. Goodson Jr. D. K. Herron H. Y. Li W. T. McMillen N. Mort S. Parsons E. C. Smith J. R. Wagner L. Yan F. Zhang J. M. Yingling 2004 Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain Bioorg. Med. Chem. Lett 14 3581 3584
7. J. Singh C. E. Chuaqui P. A. Boriack-Sjodin W. C. Lee T. Pontz M. J. Corbley H. K. Cheung R. M. Arduini J. N. Mead M. N. Newman J. L. Papadatos S. Bowes S. Josiah L. E. Ling 2003 Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI) Bioorg. Med. Chem. Lett 13 4355 4359
8. P. Bonniaud P. J. Margetts M. Kolb J. A. Schroeder A. M. Kapoun D. Damm A. Murphy S. Chakravarty S. Dugar L. Higgins A. A. Protter J. Gauldie 2005 Progressive transforming growth factor {beta}1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor Am. J. Respir. Crit. Care Med 171 889 898
9. A. C. de Gouville V. Boullay G. Krysa J. Pilot J. M. Brusq F. Loriolle J. M. Gauthier S. A. Papworth A. Laroze F. Gellibert S. Huet 2005 Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine- induced liver fibrosis Br. J. Pharmacol 145 166 177
10. E. T. Grygielko W. M. Martin C. Tweed P. Thornton J. Harling D. P. Brooks N. J. Laping 2005 Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis J. Pharmacol. Exp. Ther 313 943 951
11. J. A. Moon H. T. Kim I. S. Cho Y. Y. Sheen D. K. Kim 2006 IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy Kidney Int 70 1234 1243
12. M. O. Li Y. Y. Wan S. Sanjabi A. K. Robertson R. A. Flavell 2006 Transforming growth factor-beta regulation of immune responses Annu. Rev. Immunol 24 99 146
13. E. J. F. Franssen F. Moolenaar D. De Zeeuw D. K. F. Meijer 1994 Drug targeting to the kidney with low-molecular-weight proteins Adv. Drug Deliv. Rev 14 67 88
14. M. Haas F. Moolenaar D. K. Meijer D. De Zeeuw 2002 Specific drug delivery to the kidney Cardiovasc. Drugs Ther 16 489 496
15. J. Prakash M. Sandovici V. Saluja M. Lacombe R. Q. Schaapveld B. M. de G. H. van R. H. Henning J. H. Proost F. Moolenaar G. Keri D. K. Meijer K. Poelstra R. J. Kok 2006 Intracellular delivery of the P38 MAPK inhibitor SB202190 in renal tubular cells: a novel strategy to treat renal fibrosis J. Pharmacol. Exp. Ther 319 8 19
16. C. Duymelinck S. E. Dauwe K. E. De Greef D. K. Ysebaert G. A. Verpooten M. E. De Broe 2000 TIMP-1 gene expression and PAI-1 antigen after unilateral ureteral obstruction in the adult male rat Kidney Int 58 1186 1201
17. C. M. Lloyd A. W. Minto M. E. Dorf A. Proudfoot T. N. Wells D. J. Salant J. C. Gutierrez-Ramos 1997 RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis J. Exp. Med 185 1371 1380
18. M. Haas F. Moolenaar D. K. Meijer D. De Zeeuw 2002 Specific drug delivery to the kidney Cardiovasc. Drugs Ther 16 489 496
19. K. Ikeda K. Miura S. Himeno N. Imura A. Naganuma 2001 Glutathione content is correlated with the sensitivity of lines of PC12 cells to cisplatin without a corresponding change in the accumulation of platinum Mol. Cell Biochem 219 51 56
20. J. Reedijk 2003 New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA Proc. Natl. Acad. Sci. U. S. A 100 3611 3616
21. T. Taguchi A. Nazneen M. R. Abid M. S. Razzaque 2005 Cisplatin-associated nephrotoxicity and pathological events Contrib. Nephrol 148 107 121
22. P. M. Sutaria M. Ohebshalom T. A. McCaffrey E. D. Vaughan Jr. D. Felsen 1998 Transforming growth factor-beta receptor types I and II are expressed in renal tubules and are increased after chronic unilateral ureteral obstruction Life Sci 62 1965 1972
23. K. Fukuda K. Yoshitomi T. Yanagida M. Tokumoto H. Hirakata 2001 Quantification of TGF-beta1 mRNA along rat nephron in obstructive nephropathy Am. J. Physiol. Renal. Physiol 281 F513 F521
24. V. Vielhauer H. J. Anders M. Mack J. Cihak F. Strutz M. Stangassinger B. Luckow H. J. Grone D. Schlondorff 2001 Obstructive nephropathy in the mouse: progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 2- and 5-positive leukocytes J. Am. Soc. Nephrol 12 1173 1187
25. K. Kitagawa T. Wada K. Furuichi H. Hashimoto Y. Ishiwata M. Asano M. Takeya W. A. Kuziel K. Matsushima N. Mukaida H. Yokoyama 2004 Blockade of CCR2 ameliorates progressive fibrosis in kidney Am. J. Pathol 165 237 246
26. T. Wada K. Furuichi N. Sakai Y. Iwata K. Kitagawa Y. Ishida T. Kondo H. Hashimoto Y. Ishiwata N. Mukaida N. Tomosugi K. Matsushima K. Egashira H. Yokoyama 2004 Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis J. Am. Soc. Nephrol 15 940 948